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Abstract
Background Near-infrared (NIR) fluorescence imaging with indocyanine green (ICG) has been recently introduced for lymphatic
mapping in several tumors. We aimed at investigating whether this technology may improve the intraoperative visualization of
lymph nodes during robotic gastrectomy for gastric cancer.
Methods Between June 2014 and June 2018, a total of 94 patients underwent robotic gastrectomywithD2 lymph node dissection
for gastric cancer. In 37 patients, ICG was injected endoscopically into the submucosal layer around the tumor the day before
surgery. After propensity score matching, the results of these 37 patients were compared with the results of 37 control patients
who had undergone robotic gastrectomy without ICG injection.
Results Among the 37 patients within the ICG group, no adverse events related to ICG injection or intraoperative NIR imaging
occurred. After completion of D2 lymph node dissection, no residual fluorescent lymph nodes were left in the surgical field. A
mean of 19.4 ± 14.7 fluorescent lymph nodes was identified per patient. The mean total number of harvested lymph nodes was
significantly higher in the ICG group than in the control group (50.8 vs 40.1, P = 0.03). In the ICG group, 23 patients had
metastatic lymph nodes. The accuracy, sensitivity, and specificity of ICG fluorescence for metastatic lymph nodes were 62.2%,
52.6%, and 63.0%, respectively.
Conclusion Our study indicates that NIR imaging with ICG may provide additional node detection during robotic surgery for
gastric cancer. Unfortunately, this technique failed to show good selectivity for metastatic lymph nodes.
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Introduction
Minimally invasive surgery, including laparoscopic and robot-
ic approaches, has emerged as a valid option for the treatment
of gastric cancer, especially in the East and for patients with
early-stage tumors.1 However, the oncological efficacy of
minimally invasive techniques for the treatment of advanced
gastric cancer is still controversial. In particular, some con-
cerns have been raised regarding the possibility of carrying
out an adequate D2 lymphadenectomy during minimally in-
vasive surgery since lymph node dissection along the great
vessels is considered to be technically demanding.2,3 We hy-
pothesized that a technique that allows intraoperative identifi-
cation of draining lymph nodes from the primary tumor would
help the surgeon to perform a complete lymphadenectomy
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even during a minimally invasive procedure, such as robotic-
assisted gastrectomy.
Indocyanine green (ICG) is a diagnostic reagent that emits
fluorescence after stimulation using a laser beam or near-
infrared (NIR) light at a wavelength ≥ 820 nm. The emitted
ICG fluorescence is detected using specifically designated
scopes and camera.4 Most commonly, ICG is intravenously
administered where it binds to plasma proteins (albumin) and
from the bloodstream, it is transported to the liver and excreted
via the bile into the duodenum. Because of these properties,
ICG is considered an ideal compound for both delineation of
the extra-hepatic biliary tree and assessment of tissue perfu-
sion during gastro-intestinal surgery.5,6 Furthermore, ICG has
the property of lymphatic tropism and after submucosal or
subserosal injection, it can follow the lymphatic vessels and
accumulate in the lymph nodes. It has been reported7 that
lymphatic vessels and lymph nodes containing ICG particle
can be easily distinguished from surrounding fatty tissue using
an infrared-ray technology system. In addition, ICG deposi-
tion and fluorescence imaging are characteristically found for
prolonged periods of time in the lymph nodes (> 3 days).
Near-infrared imaging with ICG has been recently intro-
duced as a safe intraoperative technology for lymphatic map-
ping in several tumors, such as gynecological, urological, and
esophageal tumors.8–10 This technique under laparoscopic
view has also emerged as a promising tool for sentinel lymph
node mapping and dissection during early gastric cancer
treatment.7,11–13 The use of ICG has been found to offer some
advantages in lymph node visualization over other modalities
employing radioisotopes (e.g., 99mTechnetium radiocolloid)
or vital dye tracers (e.g., methylene blue, patent blue) which
are currently known to provide the best sensitivity and speci-
ficity for sentinel lymph node mapping.14 On the contrary, the
potential role and significance of fluorescent lymphography
with ICG during surgery for advanced gastric cancer has not
been completely investigated yet. In fact, only preliminary and
heterogeneous studies with either laparoscopic15 or robotic
NIR technologies16,17 have been previously published on this
issue and the reported results are not definitive.
In the present study, we analyzed the hypothesis that robot-
assisted NIR imaging with ICG could be used as an intraop-
erative lymphatic tracer method that allows detection of
lymph nodes and facilitates a more complete lymphadenecto-
my during gastrectomy.
Materials and Methods
Study Design and Data Collection
Using a prospectively collected gastric cancer database, we
identified 94 patients who underwent robotic surgery for gas-
tric cancer between June 2014 and June 2018 at the Center for
Oncologic Minimally Invasive Surgery of the University of
Florence, Italy. All the robotic gastrectomies were performed
by a single experienced surgeon (F.C.). From January 2016,
we started a study protocol to investigate the potential utility
of intraoperative NIR imaging with ICG during robotic sur-
gery for gastric cancer. A total of 37 patients were enrolled in
the study. The results of this study were compared with those
of 37 matched patients who had undergone robotic gastrecto-
mies without the use of ICG. Patient pairing was done accord-
ing to age, gender, body mass index (BMI), type of gastrecto-
my (subtotal or total), and tumor stage by using an automated
matching procedure in the SAS® software (version 8.2; SAS
Institute, Inc., Cary, NC, USA).
All patients underwent preoperative upper digestive endos-
copy with gastric biopsy and computed tomography of the
abdomen and chest. Patients with history of iodide or seafood
allergy and preoperative or intraoperative diagnosis of
enlarged/bulky lymph nodes and M1 or T4 lesions (i.e., with
distant metastases, local invasion of peritoneum, spleen or
pancreas) were excluded from the study. All patients had been
thoroughly informed about the study and gave their written
consent for the investigation in compliance with the Helsinki
Declaration and in accordance with the ethical committee of
our University Hospital, Azienda Ospedaliero-Universitaria
Careggi (Florence, Italy).
The characteristics of patients, such as age, gender, BMI,
ASA class, co-morbidities, history of abdominal surgery, peri-
operative chemotherapy, surgical outcomes (operative time,
conversion to open procedure, postoperative morbidity and
mortality, length of hospital stay), and pathological results,
were examined.
The extent of gastric resection, subtotal or total, was deter-
mined according to tumor localization, classified as upper,
middle, and lower third of the stomach. All patients received
a D2 lymphadenectomy according to the lymph node classi-
fication of the Japanese Gastric Cancer Association.18
Surgical Technique
All patients underwent either curative distal or total gastrecto-
my with D2 lymph node dissection using a da Vinci Si
Surgical System (Intuitive Surgical, Sunnyvale, CA, USA).
Robotic distal gastrectomy was performed as previously
described.19 In total gastrectomy, the same procedures for
lymph node dissection were performed as for subtotal gastrec-
tomy, but with the inclusion of a complete dissection of the left
greater omentum, division of short gastric vessels (lymph
node station n. 4a), dissection of lymph nodes along the distal
splenic artery (n. 11d), and dissection of left cardiac lymph
nodes (n. 2). The distal esophagus was transected with a linear
stapler and a Roux-en-Y intracorporeal linear side-to-side
esophagojejunal anastomosis was performed. The specimen
was pulled out through the umbilical port and either an
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intracorporeal or extracorporeal jejunum-jejunostomy was
constructed with a linear stapler.
Endoscopic ICG Injection and Intraoperative NIR
Imaging
In 37 study patients, a 0.2% (1.25 mg/ml) ICG solution was
gently injected into the submucosa layer with approximately
0.5 ml into the four quadrants around the tumor under endo-
scopic examination. The dye was injected 1 day before sur-
gery. The specific dose of ICG and the method and timing of
ICG injection were chosen on the basis of our previously
published recommendations.20 Intraoperative NIR imaging
with ICG was carried out with a near-infrared camera system
(Firefly Fluorescence Imaging Scope; Intuitive Surgical,
Sunnyvale, CA) built into the robotic platform. Lymph nodes
which had taken up ICG appeared as green spots emitting
clear fluorescence20 and were defined as the fluorescent nodes
(FNs). During surgery, the surgeon switched on the NIRmode
before and after dissection at each lymph node station. At the
end of lymphadenectomy, the dissected areas were rechecked
and any residual FNs or fluorescent tissue were additionally
removed. The removed surgical specimens were accurately
examined on the back table to retrieve, with the help of the
robotic camera, all the FNs that were not identified intraoper-
atively. Location and fluorescence status were recorded for all
the lymph nodes before they were sent for pathological anal-
ysis. In particular, the dissected lymph nodes were grouped
into five gastric lymphatic basins along the main arteries as
previously described by Kinami et al.21: left gastric artery (l-
GA), right gastric artery (r-GA), right gastroepiploic artery (r-
GEA), left gastroepiploic artery (l-GEA), and posterior gastric
artery (p-GA). The l-GA area consisted of lymph node sta-
tions 1, 2, 3, 7, and 9. The r-GA area consisted of stations 5,
8a, 8p, and 12a. The r-GEA consisted of stations 4d and 6. The
l-GEA consisted of stations 4sa and 4sb. The pGA consisted
of stations 10, 11p, and 11d.
Pathological Analysis
Clinicopathological findings such as tumor location and size,
tumor differentiation, depth of gastric wall invasion, lymph
node metastasis, and stage distribution were reviewed accord-
ing to the Japanese gastric carcinoma classification18 and the
7th edition of AJCC/TNM tumor staging.22 Tumors were also
classified according to Lauren’s histotype, i.e., intestinal, dif-
fuse, or mixed. All dissected lymph nodes were examined
histologically one slice per node and stained with H&E.
Statistical Analysis
Continuous variables were reported as mean value and stan-
dard deviation or absolute number and percentage, unless
stated otherwise. A one-tailed ANOVAwas used for analysis
of parametric data and Pearson’s Χ2 test was used for discrete
data. A P < 0.05 was considered statistically significant. All
statistical analyses, including propensity score matching, were
performed by using the SPSS software package (SPSS, Inc.,
Chicago, IL, USA).
For patients in the ICG group, the accuracy, sensitivity, and
specificity were calculated according to the number of lymph
nodes, the fluorescent, and metastasis condition of lymph
nodes. The formulas were as follows: accuracy = number of
(metastatic FNs + non-metastatic non-FNs)/number of all
lymph nodes; sensitivity = number of metastatic FNs/number
of (metastatic FNs + metastatic non-FNs); specificity = num-
ber of non-metastatic non-FNs/number of (non-metastatic
non-FNs + non-metastatic FNs).
Results
After propensity score matching, 74 pairs of ICG and control
patients were selected for final analysis. The group of patients
with ICG included 22 males and the median age was 72.2 ±
9.8. The control group included 26 males and the median age
was 72.4 ± 8.9. No statistically significant differences were
observed between the two groups according to age, gender,
BMI, ASA class, comorbidities, number of prior abdominal
operations, perioperative chemotherapy, and tumor location
(Table 1).
The operative and short-term clinical outcomes are shown
in Table 2. There were no significant differences between the
ICG and control groups with respect to extent of gastrectomy,
conversion to open surgery, operative time, postoperative
complications, and length of hospital stay. There were no
deaths up to 30 days after surgery in either group.
Pathology analyses of all patients were reviewed by one
pathologist (L.N.) skilled in upper gastrointestinal tumors.
There were no significant differences in tumor size, grade of
differentiation, and Lauren’s histotype between the two
groups (Table 3). Resection margins were negative in all pa-
tients. There were no significant differences in number of
pathological T and N categories, tumor stage distribution,
and number of metastatic lymph nodes examined between
the two study groups (Table 3). The overall mean number of
lymph nodes retrieved in the ICG group was significantly
higher than that in the control group (40.1 ± 23.0 versus
50.8 ± 17.1, P < 0.03) (Table 3). At least 15 lymph nodes were
examined in all patients in the ICG group and in 34 patients
(91.8%) in the control group. More than 30 lymph nodes were
retrieved from 35 patients (94.5%) in the ICG group and from
only 26 patients (70.2%) in the control group.
Within the ICG group, there were no patients with intraop-
erative complications related to application of NIR imaging or
adverse events attributable to endoscopic injection of ICG. In
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situ detection of fluorescence at the site of the gastric tumor
was achieved in all cases. Dye diffusion to at least one lymph
nodewas observed in 36 patients with a success rate of 97.2%.
No residual FNs were left in the surgical field after completion
of D2 lymph node dissection in all patients. The total number
of retrieved lymph nodes was 1881 and the mean number of
examined lymph nodes per patient was 50.8 (range, 23–110).
We identified 719 FNs for a mean of 19.4 (SD, ± 14.7) lymph
nodes per patient (range, 0–59). The distribution of fluores-
cent and non-fluorescent lymph nodes within the five lymph
node basins is shown in Fig. 1. All lymph node basins
contained 8 or more FNs. In particular, the highest numbers
of both total lymph nodes and FNs were retrieved in the l-GA
basin (583 and 262, respectively). The histopathological anal-
ysis indicated that 23 (62.1%) patients had metastatic lymph
nodes. The total number of metastatic lymph nodes was 150
for a mean of 4.0 lymph nodes per patient (Table 3). Of the
150 metastatic lymph nodes, 79 (52.6%) were fluorescent.
The accuracy, sensitivity, and specificity of ICG fluorescence
for metastatic lymph nodes were 62.2%, 52.6. %, and 63.0%,
respectively (Table 4).
Discussion
One crucial step in gastric cancer surgery is lymphadenectomy
since the removal of an adequate number of lymph nodes has
been shown to improve the accuracy of staging, regional dis-
ease control, and patient survival.23–26 In the present study, we
sought to evaluate the clinical value of NIR imaging with ICG
for real-time intraoperative identification of lymph nodes dur-
ing robotic surgery for gastric cancer. Our results show no
significant differences between patients who did and did not
receive ICG with respect to their clinicopathological features
and perioperative outcomes. Interestingly, we found that the
mean number of total harvested lymph nodes in the ICG group
was higher than that in the group without ICG. It is notewor-
thy that the mean number of examined lymph nodes in the
control group was 40.1, that is much higher than the recom-
m e n d e d n umb e r ( i . e . , 2 5 ) f o r a d e q u a t e D 2
lymphadenectomy27 and for proper nodal staging (i.e., 16).22
Therefore, it seems plausible that fluorescent lymphatic map-
ping with ICG can actually help the surgeon to remove resid-
ual lymph nodes that cannot be identified with the naked eye
even after a complete D2 lymphadenectomy. Alternatively,
the increase in the number of retrieved lymph nodes may be
the result of more accurate harvesting from the resected spec-
imens by means of NIR visualization, since this technique
permits the identification of even very small lymph nodes that
are difficult to distinguish from fatty tissue by manual palpa-
tion. Unfortunately, the lack of some pathological data on the
localization of retrieved lymph nodes in the control group did
not permit us to compare the number of examined lymph
nodes according to each lymph node basin in the two study
groups.








Age (years, mean ± SD) 72.4 ± 8.9 72.2 ± 9.8 0.93
Gender (%) 0.64
Male 21 (57.7) 22 (59.5)
Female 16 (43.3) 15 (40.5)
BMI (kg/m2, mean ± SD) 23.2 ± 3.04 23.3 ± 3.07 1.00
ASA (%) 0.83
Class I 1 (2.7) 2 (5.4)
Class II 24 (64.9) 23 (62.2)
Class III 12 (32.4) 12 (32.4)
Comorbidities (%) 0.23
Cardiac 11 (29.7) 12 (32.4)
Renal 1 (2.7) 0 (0)
Endocrine 6 (16.3) 4 (10.8)
Gastro-intestinal 3 (8.1) 2 (5.4)
Pulmonary 3 (8.1) 1 (2.7)
Neurological 0 (0) 2 (5.4)
Other 7 (18.9) 12 (32.4)
Previous abdominal
surgery (%)
14 (37.9) 14 (37.9) 0.74
Perioperative
chemotherapy (%)
2 (5.4) 2 (5.4) 1.00
Tumor location (%) 1.00
Lower third 20 (54.0) 23 (62.2)
Middle third 11 (29.7) 10 (27.0)
Upper third 6 (16.3) 4 (10.8)








Extent of gastrectomy (%) 0.18
Subtotal gastrectomy 25 (67.6) 30 (81.1)
Total gastrectomy 12 (32.4) 7 (18.9)
Conversion (%) 0 (0) 0 (0) 1.00
Operative time (min, mean ±
SD)
321.2 ± 77.8 293.1 ± 61 0.05
Postoperative complications (%) 1.00
Total 5 (13.5) 5 (13.5)
Respiratory 2 (5.4) 3 (8.1)
Duodenal leak 1 (2.7) 1 (2.7)
Anastomotic bleeding 1 (2.7) 0 (0)
Occlusion 1 (2.7) 1 (2.7)
Length of hospital stay (days,
mean ± SD)
10.9 ± 3.8 10.0 ± 3.8 0.34
Mortality (%) 0 (0) 0 (0) 1.00
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The efficacy of NIR imaging with ICG has been previously
proven for sentinel lymph node mapping and dissection espe-
cially in Asian countries where a significant proportion of
pa t ien ts a re d iagnosed wi th ear ly-s tage gas t r ic
cancer.7,11–13,28,29 On the other hand, the possible value of
ICG as a tracer for intraoperative lymphography with the
aim of carrying out a more complete and thorough lymphad-
enectomy is still uncertain and has been addressed only by
three previously published studies. Lan et al.17 compared 14
and 65 patients who underwent robotic gastrectomy with or
without ICG fluorescence, respectively. They did not find any
significant differences in the total number of lymph nodes
retrieved in the two groups, but all the metastatic lymph nodes
were found in the lymph node stations which showed fluores-
cence signals. In 9 out of their 14 patients, ICG was injected
intraoperatively into the subserosa around the tumor. We be-
lieve that submucosal injection of ICG solution under endo-
scopic guidance at four sites around the tumor the day before
surgery provides a better visualization of lymph nodes when
compared with intraoperative subserosal ICG injection. It is
most likely that, with intraoperative subserosal injection, the
dye does not have enough time to spread into the lymphatic
vessels and deposit into all draining lymph nodes.
Furthermore, the endoscopic submucosal injection of ICG,
unlike the subserosal approach, avoids any potential lymphat-
ic disruption that can occur with intraoperative dissection and
permits direct visualization of the lesion at the time of surgery.
Kim et al.15 investigated the value of intraoperative (15min
before dissection) submucosal injection of ICG in 15 patients
who underwent laparoscopic pylorus-sparing gastrectomy and
in 15 patients who underwent laparoscopic distal gastrectomy.
They found that fluorescent imaging with ICG may provide
additional lymph node detection especially in the infra-pyloric
area.
At the time of writing of the present manuscript, Kwon
et al.30 published the first comparative, cross-matched study
addressing the value of fluorescent-guided lymphadenectomy
during robotic gastrectomy. They analyzed the results obtain-
ed from 40 patients who underwent robotic gastrectomy with
preoperative (1 day before surgery), submucosal injection of
ICG and compared these results with those of 40 control pa-
tients who underwent the same procedure without ICG injec-
tion. They found that the mean number of overall lymph nodes
harvested was higher in the ICG group than in the historical
controls (48.9 vs 35.2, respectively), with a significantly
greater number of lymph nodes retrieved at stations 2, 6, 7,
8, and 9. Therefore, these findings are consistent with our







Tumor size (cm, mean ± SD) 3.9 ± 2.19 3.8 ± 1.9 0.94
Grade of differentiation (%) 0.12
Well differentiated 3 (8.1) 7 (18.9)
Moderately differentiated 23 (62.2) 23 (62.2)
Poorly differentiated 11 (29.7) 7 (18.9)
Lauren classification (%) 0.79
Intestinal 20 (54.1) 21 (56.7)
Diffuse 5 (13.5) 5 (13.5)
Mixed 12 (32.4) 11 (29.7)
Depth of invasion (%) 0.10
T1 7 (18.9) 6 (16.2)
T2 5 (13.5) 11 (29.7)
T3 25 (67.6) 20 (54.1)
Lymph node metastasis (%) 0.16
N0 14 (37.9) 14 (37.9)
N1 10 (27.0) 8 (21.6)
N2 4 (10.8) 6 (16.2)
N3 9 (24.3) 9 (24.3)
Tumor stage (%) 0.60
Stage I 12 (32.4) 12 (32.4)
Stage II 5 (13.5) 9 (24.3)
Stage III 20 (54.1) 16 (43.3)
No. of metastatic lymph nodes
(mean ± SD)
4.4 ± 6.8 4.0 ± 5.4 0.75
No. of harvested lymph nodes
(mean ± SD)




















l-GA l-GEA p-GA r-GEA r-GA
Fluorescent nodes Non-fluorescent nodes
Fig. 1 Distribution of fluorescent and non-fluorescent lymph nodes with-
in the five lymph node basins. l-GA, left gastric artery; l-GEA, left
gastroepiploic artery; p-GA, posterior gastric artery; r-GEA, right
gastroepiploic artery; r-GA, right gastric artery
Table 4 Number of total lymph nodes, metastatic lymph nodes, and




Fluorescent lymph nodes 79 640
Non-fluorescent lymph nodes 71 1091
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results and confirm that NIR lymphography with ICG can
facilitate effective visualization of draining lymph nodes and
allows assessment of the thoroughness of the lymphadenecto-
my intraoperatively. However, one limitation of the study by
Kwon et al.30 is the enrollment of patients with early-stage
disease (35 patients with T1 tumors and 5 patients with T2
tumors) with a low incidence of lymph node metastases (only
5 patients with one metastatic lymph node each). As a conse-
quence, the authors were not able to determine metastatic
lymph node–specific sensitivity or specificity of FNs.
In our present study, 23 out of 37 patients were N positive
with a total of 150 metastatic lymph nodes retrieved. Our
preliminary results seem to indicate that ICG fluorescence in
gastric cancer has low diagnostic value for metastatic lymph
nodes: in fact, the accuracy, sensitivity, and specificity for this
purpose were far less than 90%. Moreover, the number of
retrieved metastatic lymph nodes was similar in the two study
groups. However, our findings are not surprising in light of
previous studies on sentinel lymph node detection in early
gastric cancer. The most common cause of a false negative
result in sentinel node mapping has been reported to be an
obstructed lymphatic vessel by cancer cells or a massive can-
cerous invasion of the lymph node.14 In such cases, the ad-
ministered tracer cannot accumulate into the positive lymph
node and migrate into second tier nodes. This is the reason
why sentinel node technique is not considered feasible in gas-
tric tumors ≥ T2 that are associated with high risk for metasta-
tic lymph nodes. Therefore, neoplastic permeation of lym-
phatic vessels and massive infiltration of lymph nodes may
explain the poor selectivity of ICG for metastatic lymph nodes
in our 23 N-positive patients.
The present study had some limitations. First of all, we
used the propensity score matching method to identify the
two study groups so as to overcome the limitations due to
the non-randomized, retrospective nature of the trial.
Secondly, our study includes only a small patient sample
and was conducted in a single academic institution, thus en-
rolling only one experienced surgeon and pathologist. Future
large-sized multi-institutional prospective randomized trials
are needed to truly determine the clinical impact of intraoper-
ative lymphatic mapping with ICG fluorescence on gastric
cancer surgery.
Conclusion
The results of the present study should be interpreted with
caution because of its retrospective nature. However, our find-
ings suggest that intraoperative lymphatic mapping with ICG
can help the surgeon to identify those lymph nodes left behind
by observation with the naked eye and assess the thorough-
ness of the lymphadenectomy during robotic gastrectomy,
thus increasing the number of examined lymph nodes and
improving tumor staging. Unfortunately, NIR imaging with
ICG failed to show good selectivity for metastatic lymph
nodes.
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